Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 2/20 | 0.37 |
| ▸ | CES1 | P23141 | 2/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.35 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.35 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.35 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.34 |
| ▸ | ASPH | Q12797 | 2/20 | 0.34 |
| ▸ | KDM8 | Q8N371 | 2/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL232644 | 0.83 | ALB (0.41) | ALBALDH1A1ALOX15CYP1A2CES2 | |
| SCHEMBL1476008 | 0.81 | DGAT1 (0.41) | ALDH1A1ALOX15CES2CES1KDM4E | |
| SCHEMBL7246452 | 0.81 | SMN1; SMN2 (0.36) | ALDH1A1ALOX15CES2CES1CYP3A4 | |
| SCHEMBL490677 | 0.79 | ALDH1A1 (0.48) | ALDH1A1ALOX15CYP1A2NAPRTKDM4E | |
| SCHEMBL1196449 | 0.78 | KDM4E (0.47) | ALDH1A1ALOX15CYP1A2KEAP1NAPRT | |
| SCHEMBL1477248 | 0.76 | AR (0.38) | ALDH1A1ALOX15CES2CES1KEAP1 | |
| SCHEMBL1476023 | 0.76 | GAA (0.56) | ALDH1A1KDM4EHPGDSMN1; SMN2MEN1 | |
| SCHEMBL1476818 | 0.76 | KMT2A (0.41) | ALDH1A1CYP1A2KDM4ECA1CA2 | |
| SCHEMBL3181993 | 0.76 | ALDH1A1 (0.48) | ALDH1A1ALOX15CYP1A2NAPRTKDM4E | |
| SCHEMBL2553639 | 0.76 | ALDH1A1 (0.42) | ALDH1A1ALOX15CYP1A2KDM4ECYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230148214-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. | 2023-05-11 | — | — | US | claimed |
| WO-2021178780-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. (US) | 2021-09-10 | — | — | WO | claimed |
| CN-110143945-A | A kind of simple and convenient process for preparing of 4- substituent group methyl-1-(2H) phthalazone | 新发药业有限公司 | 2019-08-20 | — | — | CN | claimed |
| US-9682940-B2 | Indazole derivatives useful as CB-1 inverse agonists | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-20 | — | — | US | claimed |
| WO-2017034872-A1 | INDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-02 | — | — | WO | claimed |
| US-20170057925-A1 | INDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-02 | — | — | US | claimed |
| US-7659281-B2 | HMG-CoA reductase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-09 | — | — | US | claimed |
| EP-1648886-B1 | BENZOXAZINONE-DERIVED SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | ESTEVE LABOR DR (ES) | 2009-12-09 | — | — | EP | claimed |
| EP-1732552-A4 | 2,6-DISUBSTITUTED PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO INC (US) | 2007-12-19 | — | — | EP | claimed |
| US-20070249583-A1 | HMG-CoA reductase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-25 | — | — | US | claimed |
| US-20070032482-A1 | Benzoxazinone-derived sulfonamide compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-02-08 | — | — | US | claimed |
| EP-1732552-A2 | 2,6-DISUBSTITUTED PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Merck & Co., Inc. (US) | 2006-12-20 | — | — | EP | claimed |
| CN-1860114-A | Benzoxazinone-derived sulfonamide compounds, process for their preparation and their use as pharmaceuticals | ESTEVE LABOR DR (ES) | 2006-11-08 | — | — | CN | claimed |
| EP-1648886-A1 | BENZOXAZINONE-DERIVED SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-04-26 | — | — | EP | claimed |
| WO-2005070133-A2 | 2,6-DISUBSTITUTED PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2005-08-04 | — | — | WO | claimed |
| WO-2005014589-A1 | BENZOXAZINONE-DERIVED SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE S.A. (DE) | 2005-02-17 | — | — | WO | claimed |
| US-20230148214-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. | 2023-05-11 | — | — | US | disclosed |
| WO-2021178780-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. (US) | 2021-09-10 | — | — | WO | disclosed |
| EP-1487455-A1 | MORPHOLINE DERIVATIVES SUBSTITUTED AT THE 2-POSITION BY AN ARYLALKYLUREA GROUP FOR USE AS CCR-3 ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY CONDITIONS | GLAXO GROUP LIMITED (GB) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003082292-A1 | MORPHOLINE DERIVATIVES SUBSTITUTED AT THE 2-POSITION BY AN ARYLALKYLUREA GROUP FOR USE AS CCR-3 ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY CONDITIONS | GLAXO GROUP LIMITED (GB) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249583-A1 | HMG-CoA reductase inhibitors | HMGCR, LDLR, PCSK9 | ALB 410/4885ALDH1A1 1255/4885ALOX15 850/4885 |
| US-20230148214-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | LRRK2, PARK7, GDI2 | ALB 4818/4885ALDH1A1 1904/4885ALOX15 3451/4885 |
| US-20070032482-A1 | Benzoxazinone-derived sulfonamide compounds, their preparation and use as medicaments | HTR6, HTR5A, P2RX6 | ALB 3781/4885ALDH1A1 1597/4885ALOX15 283/4885 |
| US-20170057925-A1 | INDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | CNR1, GPR119, CNR2 | ALB 4269/4885ALDH1A1 689/4885ALOX15 1393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.